IMBRUVICA® (ibrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor approved to treat Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Waldenström’s Macroglobulinemia and Relapsed/Refractory Marginal Zone Lymphoma and currently being evaluated in multiple types of cancer and for other serious diseases.
Type of Molecule
Small Molecule
Target
BTK
Region
US, EU
| Potential Indication | Product Type | Phase (1, 2, 3, Submitted, Approved) |
|---|---|---|
| Diffuse Large B-cell Lymphoma (DLBCL) | New Indication | Phase 3 |
| Follicular Lymphoma (FL) | New Indication | Phase 3 |
| Relapsed/Refractory Marginal Zone Lymphoma (MZL) | New Indication | Phase Approved Approved |
| Acute Myeloid Leukemia (AML) | New Indication | Phase 2 |
| Multiple Myeloma (MM) | New Indication | Phase 2 |
| Pancreatic Cancer | New Indication | Phase 3 |
| Solid Tumors | New Indication | Phase 2 |
| Chronic Graft versus Host Disease (cGVHD) | New Indication | Phase Approved Approved |